Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its stake in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 118.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 260,509 shares of the company’s stock after purchasing an additional 141,002 shares during the period. GSA Capital Partners LLP’s holdings in Ovid Therapeutics were worth $307,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in Ovid Therapeutics by 22.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock worth $54,000 after purchasing an additional 3,145 shares during the period. BNP Paribas Financial Markets grew its position in shares of Ovid Therapeutics by 74.7% during the 1st quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock valued at $98,000 after acquiring an additional 13,756 shares during the period. DCF Advisers LLC grew its position in shares of Ovid Therapeutics by 111.6% during the 2nd quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock valued at $32,000 after acquiring an additional 22,020 shares during the period. FFT Wealth Management LLC grew its position in shares of Ovid Therapeutics by 18.2% during the 2nd quarter. FFT Wealth Management LLC now owns 489,552 shares of the company’s stock valued at $377,000 after acquiring an additional 75,530 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Ovid Therapeutics during the 3rd quarter valued at about $102,000. 72.24% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Trading Down 0.9 %

OVID stock opened at $1.05 on Friday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics Inc. has a 12-month low of $0.68 and a 12-month high of $4.10. The stock has a market cap of $74.56 million, a price-to-earnings ratio of -2.23 and a beta of 0.41. The business’s 50-day moving average is $1.16 and its 200 day moving average is $1.47.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.15 million. On average, sell-side analysts anticipate that Ovid Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Ovid Therapeutics in a research report on Monday, September 30th. William Blair upgraded Ovid Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $4.04.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.